Pathogenic variants in the glucocerebrosidase gene (GBA) encoding the enzyme deficient in Gaucher's disease (GD) are associated with Parkinson's disease (PD). To investigate the sequence variants, their association with PD and the related phenotypes in a large cohort of European, mostly French, patients and controls, we sequenced all exons of GBA in 786 PD patients from 525 unrelated multiplex families, 605 patients with apparently sporadic PD and 391 ethnically matched controls. GBA mutations were significantly more frequent (odds ratio 5 6.98, 95% confidence interval 2.54 -19.21; P 5 0.00002) in the PD patients (76/1130 5 6.7%) than in controls (4/391 5 1.0%) and in patients with family histories of PD (8.4%) than in isolated cases (5.3%). Twenty-eight different mutations were identified in patient and control groups, including seven novel variants. N370S and L444P accounted for 70% of all mutant alleles in the patient group. PD patients with GBA mutations more frequently had bradykinesia as the presenting symptom and levodopa-induced dyskinesias. The phenotype was similar in patients with one, two or complex GBA mutations, although the two patients with c.1263del1RecTL and N370S/RecD55 mutations had signs of GD. Segregation analyses in 21 multiplex families showed that 17% of the affected relatives did not carry GBA mutations found in the given family, indicating heterogeneity of the aetiology, but 46% of the unaffected relatives were GBA mutation carriers. These genotype and clinical analyses on the largest homogeneous sample of European patients studied to date confirmed that GBA mutations are the most common genetic risk factor for PD, particularly in familial forms.
INTRODUCTION
Monogenic Parkinson's disease (PD), caused by mutations in leucine-rich repeat kinase 2 (LRRK2), a-synuclein (SNCA), parkin, PTEN-induced kinase 1 (PINK1) and DJ-1, is rare (1) . Most PD result from complex interactions between genes and/or environmental factors. Genetic variations may modify penetrance, age at onset, severity and progression. October 14, 2010 glucocerebrosidase (GBA) are emerging as relevant susceptibility factors for PD in several populations (1) .
GBA mutations cause Gaucher's disease (GD), a recessive glycolipid storage disorder caused by b-glucocerebrosidase deficiency. Three types of GD are distinguished according to the associated neurological symptoms (2) . Although there was no significant overlap between GD and PD phenotypes, the indication for a relationship between the two conditions came with the observation of the occurrence of parkinsonism and Lewy body pathologies in patients with GD and their relatives and the identification of GBA mutations in patients with PD (3) . Subsequent genotyping studies have shown an increased frequency of GBA mutations in cohorts of PD patients with different geographical or ethnical origins and particularly in those with early onset (4 -10) . GBA mutations are more common in the Ashkenazi Jewish population ( 20% of patients with typical parkinsonism and 4% of controls), the N370S mutation ( 70% of mutant alleles) being the most frequent (8, 11) ; they are less frequent and more diverse in other ethnic groups (11) . However, carrier frequency in non-Ashkenazi Jewish populations was 3%, in a study by 16 international centres, but increased to 7% in subpopulations in which the gene was fully sequenced, showing that limited screening may miss more than half of the mutant alleles (11) . To accurately ascertain the frequency and the spectrum of GBA mutations in Europe, we screened the entire GBA gene in the largest series of PD patients and relatives analysed so far and in ethnicity-matched controls. Clinical features of PD patients with and without GBA mutations were compared.
RESULTS

Mutations in GBA and frequency of mutation carriers
GBA variants were identified in 44 families (8.4%) and 32 isolated cases (5.3%) ( Available affected relatives (n ¼ 260) were also screened. In 21 of the 44 families carrying GBA variants, at least one additional first-or second-degree affected relative carried a mutation (n ¼ 29); patients in five of these families were discordant for the GBA variant (24%) (Fig. 1) . Thus, 100 individuals from 76 families carried at least one mutated allele: 21 missense variants, six of which were novel, one nonsense mutation (S173X) and five multiple amino acid substitutions designated as 'complex' or 'recombinant' (Rec) alleles that presumably arose by cross-over of the functional GBA gene with a nearby pseudogene GBAP (12) ( Table 1) .
The common N370S mutation was found in 28 patients from 21 multiplex families, 14 isolated cases (39 heterozygotes and three homozygotes) and two controls (heterozygotes). The risk of N370S mutation carriers for PD (35/ 1130, 3.1%) compared with European controls (2/391, 0.5%) was 6.22 (CI 1.49 -25.98; P ¼ 0.0008). L444P, the second most frequent GBA mutation, was found in 13 patients from eight multiplex families (12 heterozygotes and one homozygote) and four heterozygous isolated cases (12/1130, 1.1%), but not in controls (P ¼ 0.09). Two related patients had two mutations, N370S and L444P, that were usually reported in trans in GD patients. We thus considered these patients as potential compound heterozygotes. One patient was shown to be compound heterozygous for N370S/RecD55 (Fig. 1) , a 55 bp deletion in exon 9 resulting from recombination between GBA and GBAP (c.1263 -1317 del) (13) . Four unrelated patients carried L444P on three different recombinant alleles: RecNciI (L444P, A456P, V460V) (0.18%), RecA456P (L444P, A456P) (0.09%) and the rare complex mutations, c.1263del+RecTL (c.1263 -1317del, D409H, L444P, A456P, V460V) (0.09%). Together, N370S and L444P accounted for 70% (53/76) of mutant alleles in this series of European PD patients (Fig. 2) .
The other variants were found only once or twice ( Table 1 ). The nonsense mutation S173X predicted to result in a truncated protein was found in one patient and her child (Fig. 1) . One patient carried the complex allele D140H + E326K shown to produce a Type 1 GD phenotype (14) . The remaining 20 amino acid substitutions, including six new nonsynonymous variants (G80R, G113A, I119L, S125N, P246L and P452L) ( Table 1) , were each found in a single family. Of note, E388K, previously identified in two Portuguese controls (15) , was found in one PD patient and one control. Two novel silent variants were also detected, A190A and A446A, the latter in combination with the newly identified G113A substitution. These novel sequence changes were not found on the 782 control chromosomes. Most amino acids affected by these variants, except for G113A, are highly conserved among mammals down to Monodelphis domestica (I119L, P246L and E388K) or Tetraodon nigroviridis (G80R and S125N) (Supplementary Material, Fig. S1 ). Interestingly, P452 was highly conserved across all species down to Caenorhabditis elegans, suggesting that the P452L variant might be pathogenic. S125N, the only new variant that could be analysed for co-segregation, co-segregated with the disease (Fig. 1) . Segregation analyses in 21 multiplex families showed that 17% (5/29) of the affected relatives did not carry the GBA mutation in their family, indicating a heterogeneous aetiology. However, 46% (23/50) of the unaffected relatives of GBA carrier patients were also GBA mutation carriers (mean age at examination 52.5 + 14.7 years, range 29-81), indicating that not all GBA mutation carriers develop PD. Interestingly, a 63-year-old asymptomatic woman was homozygous for the severe Y304C mutation (FPD485) (Fig. 1) . In addition to the N370S mutation, the novel non-synonymous K79M variant and the synonymous Y313Y variant were found exclusively in one control subject each. None of the GBA carriers had the LRRK2 G2019S mutation.
Two variants, E326K and T369M, previously described as non-pathogenic polymorphisms in patients with GD (11), were significantly associated with PD. The E326K substitution, suggested to be a neutral single nucleotide (14), was identified in 49 unrelated index cases (41 heterozygotes, two compound heterozygotes with N370S, six homozygotes including one in combination with D140H; allelic frequency: 2.4%) and in eight control subjects, all in the heterozygous state (allelic frequency: 1.0%), reflecting a trend towards an association with the disease (OR ¼ 2.41, 95% CI 1.14 -5.08; P ¼ 0.02). The neutral T369M polymorphism was found in 17 unrelated PD patients (14 heterozygotes including one in combination with the complex c.1263del+RecTL mutations and three The arrows point to the probands. To protect confidentiality, genders of some individuals are not shown. AE, age at examination; AO, age at onset; +, wild-type; M, heterozygote mutated.
homozygotes; allelic frequency: 0.88%) and in one control subject in the heterozygous state (allelic frequency: 0.13%).
The allelic frequency of the T369M substitution was marginally higher in the PD sample than in controls (OR ¼ 6.97, 95% CI 0.93-52.02; P ¼ 0.03).
Age at onset in carriers of GBA mutations with PD
The mean age at onset of PD in GBA mutation carriers was 51.0 + 12.7, comparable to that of non-carriers (50.0 + 13.7) ( Table 2 ). The frequency of GBA mutations was similar in patients with early (6.2%, 42/681) and late onset (8.5%, 54/ 635) PD (OR ¼ 0.71, 95% CI 0.47-1.08; P ¼ 0.10).
When stratified according to their deduced or observed effects on phenotype in patients with GD (mild GBA mutations are associated with non-neuronopathic Type 1 GD and severe or null mutations with severe neuronopathic Type 2 or Type 3 disease) (2, 8, 16) , 46/100 PD patients had mild GBA mutations (R329C, N370S, D140H and G377S) and 43 null or severe mutations (R120W, R131C, S173X, G202R, Y304C, S364N, D409H, L444P, R463C, R463H, RecD55, RecNciI, RecA456P and c.1263del+RecTL) (2, 17, 18) . The 11 PD carriers with new GBA variants (G80R, G113A, I119L, S125N, P246L and P452L) and previously reported variants of unknown pathogenicity [K(227)R, T323I and E388K] were not included in the analyses. PD onset tended to be earlier in carriers of severe GBA mutations (48.3 + 13.5 years) than in those with mild mutations (53.2 + 10.4 years; P ¼ 0.06), particularly among isolated cases (39.3 + 12.0 years in carriers of severe mutations compared with 50.8 + 9.8 years in those with mild mutations; P ¼ 0.008). When GBA mutations were stratified according to their type, an earlier age at onset was observed in patients with null or complex alleles (41.2 + 10.1 years, n ¼ 9) than in those with missense mutations (52.1 + 11.9 years, n ¼ 76; P ¼ 0.01). Although two controls carried the mild N370S mutation (0.05%), none carried severe mutations.
Clinical characteristics of mutation carriers (Table 2)
Carriers and non-carriers had similar sex distributions, ages at onset and examination, disease durations, motor manifestations on examination and mini mental state examination (MMSE) score. Interestingly, mutation carriers more frequently had bradykinesia at onset (73%) than non-carriers (60%; P ¼ 0.014). They also had levodopa-induced dyskinesias more frequently (62%) than non-carriers (50%; P ¼ 0.037), independently of gender, dose of levodopa, disease and treatment durations (data not shown).
PD patients with two or complex GBA mutations
Eight PD patients carried two or complex GBA mutations, including one with the complex mutations, c.1263del+RecTL. Full clinical data were not available for one of the two patients with the N370S/L444P mutations. All but one patient had typical PD with asymmetric akinesia, rigidity and/or rest tremor, levodopa responsiveness, levodopa-induced dyskinesias and motor fluctuations. The average age at PD onset was 53.6 + 17.2 years (range 21 -72), like patients with single mutations (50.8 + 12.4 years, range 16-73). Five had no atypical symptoms, in particular no signs of GD. Because of the combination of levodopa responsiveness with disabling levodopa-induced dyskinesias, one patient with homozygous N370S mutation and onset at 52 was treated by chronic bilateral stimulation of the subthalamic nucleus (STN), which improved the asymmetric akinesia, rigidity and rest tremor as well as the motor fluctuations and dyskinesias; the patient is still improved at age 78. One PD patient was secondarily diagnosed with GD and another had clinical features suggestive of the GD phenotype, despite no formal diagnosis of GD. Due to complex neurological and extra-neurological features such as osteopenia, a large metabolic screening, including b-glucocerebrosidase levels in serum, was performed in the first patient who was compound heterozygous for N370S/RecD55, leading to the diagnosis of GD. At the age of 44, he had symmetrical levodopa-responsive parkinsonism with cervical dystonia, dysarthria and cognitive impairment (MMSE 22/30). Oculomotor movements were normal. Levodopa-induced dyskinesias and motor fluctuations appeared progressively. When examined a second time, he had no haematological or liver abnormalities, but osteopenia and decreased serum levels of b-glucocerebrosidase [0.9 nmol/mg protein/h (normal range 6.5 -10.5)] were RecNciI, RecA456P, c.1263-1317del + RecTL. 'Other alleles' included K(227)R, G80R, G113A, I119L, R120W, S125N, R131C, D140H + E326K/E326K, S173X, P246L, Y304C, T323I, S364N, G377S, E388K, D409H, P452L, R463C, R463H and RecD5.
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Human Molecular Genetics, 2011, Vol. 20, No. 1 observed. Imiglucerase treatment did not provide obvious functional benefit. The second patient, carrying c.1263del+RecTL, had levodopa-responsive asymmetric parkinsonism and rest tremor at the age of 21, in association with segmental dystonia, mild supranuclear gaze palsy, mild pyramidal tract dysfunction and diffuse dorso-lombar pain. Brain magnetic resonance imaging was normal, but the DAT (Dopamine Transporter) scan showed severe bilateral dopaminergic denervation. Copper and ceruloplasmin serum levels were normal. Within 2 years, her status deteriorated, with postural instability, axial hypotonia and depression, and she finally became wheelchair bound at age 23. Because of levodopa-induced dyskinesias and motor fluctuations, bilateral STN chronic stimulation was begun when she was 24. Two years after the beginning of the bilateral STN chronic stimulation, the patient still had some clinical benefits, but the axial unified Parkinson's disease rating scale (UPDRS) motor score deteriorated due to postural instability.
DISCUSSION
This study of GBA mutations in a total of 1782 individuals from multiplex PD families and isolated cases and controls is one of the largest sequencing studies of GBA mutations reported. It allowed us to accurately estimate the frequency of mutations and to identify multiple rare variants, seven of which were novel mutations. These results validate the association between GBA mutations and PD reported in a recent, large multicentre analysis (11) and, in addition, provided data from combined mutational, segregation and clinical analyses in a large and homogeneous European cohort. This enabled us to identify a sufficient number of carriers to assess the influence of the nature of the mutations on the phenotype of patients (8, 16) . Furthermore, this ethnically homogeneous and clinically well-defined subset of European PD patients allowed us to compare the phenotypes of patients with and without GBA mutations, recruited according to the same criteria. The large number of patients with familial (n ¼ 525) and isolated (n ¼ 605) PD yielded an accurate estimate of the frequency of GBA mutations in PD patients. Finally, since all available affected (n ¼ 260) and unaffected (n ¼ 50) relatives were also analysed, we were better able than previously (6, 9, 19) to evaluate the concordance of GBA mutation carriers within PD families.
In all, GBA variants were detected in 100 patients from 76 different PD families and isolated cases for an overall carrier frequency of 6.7%, which was significantly greater than in controls (1.0%, OR ¼ 6.98). However, the frequency was significantly higher in multiplex families than in isolated cases. Although our results replicate the most robust and consistent associations of GBA mutations with PD in previous studies (3,4,6,8 -11,15,19-25) , current genome-wide association studies (26) (27) (28) Human
have not confirmed this association. The present results, however, have greatly expanded on those obtained in the recent meta-analysis, in which 297 isolated PD patients and 251 control subjects of the present cohort were genotyped for only three common GBA mutations (4% in patients and 0.4% in controls) (11) , and demonstrate the need to sequence all exons and intronic regions of the GBA gene, particularly in nonAshkenazi Jewish populations, to accurately estimate the frequency of mutations and to identify the multiple rare variants in patient and control groups. We would have missed 30% of the mutant alleles in the present series of PD patients and 50% in the controls if only the two most common mutations, N370S and L444P, were analysed. The most common mutation in the present study, N370S, found on 46% of the mutant alleles, was six times more frequent in the PD group than in controls. It was also the most frequent in Ashkenazi Jewish (.70%) and Portuguese PD patients (36%) (15) . Of note, N370S was rarely found in Asian patients and controls (7, 19, 21, 22, 29) , but L444P was found regardless of ethnic background, and is the most frequent mutation in the non-Ashkenazi Jewish PD population (11) . GBA variants were identified in 44 of the 525 multiplex families, 21 of which were assessed for co-segregation. The rate of discordance within families (24%) was lower than that in previous studies (6, 9) . Among discordant families, Nichols et al. (9) observed an earlier age at PD onset in patients with pathogenic GBA variants than those without. Carriers of pathogenic mutations in our five discordant families also had a lower mean age at onset (50.3 + 11.5 years) than those without (62 + 18.7 years). However, 46% of the unaffected family members also carried the GBA mutations, including an asymptomatic 63-year-old woman with the homozygous Y304C mutation. Their ages at examination, ranging from 29 to 81 years, indicate age-dependent and reduced penetrance. Fourteen out of the 23 unaffected relatives were older than the mean age at onset of PD patients with GBA mutations at the time they were examined.
PD onset tended to be earlier in carriers of severe GBA mutations, particularly in those with null or recombinant alleles. Interestingly, one carrier of the severe L444P GBA mutation and another with c.1263del+RecTL had juvenile PD (onset at 20 and 21 years, respectively). Of note, severe GBA mutations were not found in controls. Interestingly, we found eight PD patients with two or complex GBA mutations, including two patients with c.1263del+RecTL and N370S/ RecD55, who had typical PD with early age at onset (21 and 45 years, respectively) and clinical features suggestive of GD.
Clinically, patients with GBA mutations were more likely to have family histories of PD and bradykinesia as presenting symptoms of PD; dyskinesias also tended to be more frequent, as previously shown (6), independently of gender, dose of levodopa, disease and treatment durations. However, in contrast with previous reports of an earlier age at onset, a higher male to female ratio and more cognitive changes among GBA mutation carriers (3,4,6,8,9,11,19-21, 23-25,30) , we found no significant differences between mutation carriers and non-carriers. In addition, the phenotype of PD patients with single GBA mutations, and most carriers of two mutations, was similar to that of PD patients with no mutations. Thus, PD patients carrying two or complex GBA mutations may be suitable for chronic bilateral STN stimulation, as illustrated by the two cases we report. However, further studies are needed to confirm these results.
In conclusion, this large study reinforces the role of GBA as a major risk factor for PD. The next challenge will be to elucidate how GBA mutations lead to PD. Increasing evidence suggests that mutant b-glucocerebrosidase protein is related to the abnormal handling and clearance of a-synuclein that result in Lewy body pathologies. If b-glucocerebrosidase misfolding and impaired trafficking contribute to the development of PD in GBA mutation carriers, then chaperone-mediated therapy may be a therapeutic or preventive option to treat these patients (31) .
MATERIALS AND METHODS
Subjects
Patients were recruited through the French network for the study of Parkinson's Disease Genetics (PDG). Local Ethics Committees approved the study, and written informed consent was obtained from all participants.
The study included 1391 PD patients, 786 patients from 525 unrelated multiplex families and 605 isolated PD cases, mostly from France (89%) ( Table 3) . Patients underwent standard neurological examinations, including the UPDRS, the Hoehn and Yahr scale, response to levodopa and the MMSE to evaluate cognitive function. Most (.80%) fulfilled the criteria for definite PD (32) . Familial parkinsonism was defined by a positive family history compatible with PD in at least one first-or second-degree relative. For co-segregation analyses, available DNA from unaffected family members (n ¼ 50) was also tested for the corresponding GBA mutations. The controls, 391 ethnicity-matched subjects without family histories of PD, mainly spouses of patients, included 210 females and 181 males examined at age 59.3 + 11.0 (range 31 -85).
Patients with Parkin-, PINK1-and DJ-1-associated recessive parkinsonism, with an early age at onset (,45 years), were excluded. All subjects were screened for the LRRK2 G2019S mutation, by direct sequencing of exon 41 (32) or by Taqman Assay-by-Design SNP method (33) using SDS v2.0.1 on ABI 7500 HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA), and any mutations identified were verified by direct sequencing.
Molecular analyses
Peripheral blood was collected from each patient, and DNA was extracted from leucocytes according to standard procedures. Exons and flanking intronic regions of GBA were sequenced in all patients and controls. To avoid amplifying and sequencing the neighbouring pseudogene, GBA was amplified in three large fragments (a 2972 bp fragment encompassing exons 1 -5; a 2049 bp fragment encompassing exons 5-7 and a 1682 bp fragment encompassing exons 8 -11), using previously described primers and a unique 648C to 548C touch-down PCR program (Supplementary Material, Table S1 ). PCR products were sequenced with internal primers, adjacent to coding exons and exon -intron boundaries, using the Big Dye Terminator Cycle Sequencing 
Statistical analyses
Mutation frequencies were calculated counting one carrier per family. Demographic and clinical characteristics of mutation carriers and non-carriers were compared with the x 2 or Fisher's exact tests for categorical variables and the MannWhitney U-test for continuous variables (significant at P , 0.05). ORs were calculated with a 95% CI for association between GBA mutations and PD. 
